# Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections

> **NCT02045797** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 126 (actual)

## Conditions studied

- Infections, Bacterial

## Interventions

- **DRUG:** GSK2140944 Lyophile
- **DRUG:** GSK2140944 Capsules

## Key facts

- **NCT ID:** NCT02045797
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-24
- **Primary completion:** 2015-06-29
- **Final completion:** 2015-06-29
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2017-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02045797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02045797, "Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02045797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*